All In MedTech

Device Trial Radar · NCT03783884

A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 223 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

223

Actual

Start

Jun 14, 2019

Primary completion

Dec 28, 2022

Study completion Jan 27, 2023

Sponsor

Lead sponsor
Lungpacer Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 21, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts. The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.

Conditions

  • Ventilator Induced Diaphragm Dysfunction (VIDD)

Interventions

  • Lungpacer Diaphragm Pacing TherapyDevice

    Transvenous phrenic nerve stimulation to induce diaphragm contraction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Successful WeaningTime frame: Through Day 30
  2. Adverse Event ProfileTime frame: 30 days

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Stanford University Medical Center

    Stanford, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Florida, Shands

    Gainesville, Florida

30 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.